The market is buzzing with demand for weight problems capsules, however Allurion Applied sciences is constructing a case that its weight reduction platform—a medical gadget and software program—is a worthy competitor to those medication and maybe even a companion to them. The corporate made debuted on the inventory market debut Wednesday, elevating $100 million to assist commercialization of its medical know-how globally and proceed the scientific testing to assist an FDA submission within the U.S.
Allurion went public in a SPAC merger with Compute Well being. Shares of Allurion opened on the New York Inventory Change Wednesday at $9 apiece, which was the inventory’s peak. On the finish of its first day as a publicly traded firm, shares closed at $7.25 every. The Natick, Massachusetts-based firm’s shares commerce beneath the inventory image “ALUR.”
Allurion’s know-how is a gastric balloon within the type of a capsule that sufferers swallow. The balloon inflates within the affected person in a 15-minute outpatient process. Whereas the balloon is in place over about 4 months, sufferers really feel fuller so that they eat much less. The Allurion platform features a scale, watch, and a cellular app that screens weight reduction and employs synthetic intelligence and machine learning-techniques to investigate affected person knowledge collected by the system. Along with offering insights to information a affected person’s progress, the know-how additionally allows distant monitoring. Allurion co-founder and CEO Shantanu Gaur informed MedCity Information that this method is meant to result in everlasting behavioral modifications that final lengthy after the capsule deflates and passes out of the digestive system.
Since receiving advertising authorization in Europe in 2016, Allurion’s know-how has been accredited in a number of different international locations. The product is indicated for individuals with a physique mass index better than 27, which Gaur mentioned represents between 500 million and 1 billion individuals outdoors of the U.S. To date, the system has handled about 100,000 individuals in additional than 50 international locations. Publish-marketing analysis reveals that sufferers lose a median of 15% of their weight after 4 months, Gaur mentioned. These outcomes are comparable to at least one 12 months on Wegovy, the GLP-1 agonist weight problems drug from Novo Nordisk that’s in excessive demand. Gaur mentioned the market alternative for GLP-1 agonists is $75 billion to $100 billion in income by 2030. However these financial fashions assume that 5% to 10% of sufferers start remedy.
“What concerning the different 90 to 95%?” Gaur mentioned. “What about those that begin a drug after which cease? I believe it’s a large alternative. Due to these medication, there’s an exponential rise in consciousness about weight problems and extra weight as one thing you’ll be able to go to your physician and discuss. As a result of that dialog is going on at an exponential fee, that may be a main tailwind for our enterprise.”
Within the first quarter of this 12 months, Allurion reported $14 million in income, a greater than 10% enhance in comparison with the identical interval within the prior 12 months. The corporate goals to ramp up gross sales by way of a brand new commercialization alliance with medical gadget big Medtronic. The deal signed in June allows Allurion to leverage Medtronic’s bariatric channels in Central and Jap Europe, the Center East, and Africa, Gaur mentioned. Bariatric surgeons in these channels might use Allurion’s balloon and software program for sufferers who don’t wish to have surgical procedure. For sufferers who do elect surgical procedure, Allurion’s software program should still be of extra assist. The deal expands entry to Allurion’s know-how, whether or not it’s the balloon and the software program or simply the software program, Gaur mentioned.
Future companions might embrace giant pharmaceutical corporations, Gaur mentioned. Sufferers who take GLP-1 medication nonetheless want a dietary or well being coach to reply questions and information the affected person on what to eat and tips on how to train.
“That’s all being completed by human beings,” Gaur mentioned. “What we’ve discovered is thru a big language mannequin like GPT, you’ll be able to create a coach that’s skilled on our weight reduction program. Why not have a totally automated answer to triage requests, unlock extra time and sources for people?”
Allurion’s analysis contains growing a totally automated coach that would fill the position of a human however be accessible to customers 24 hours a day, seven days every week. Gaur mentioned this Allurion coach might probably be used with weight problems medication as approach to handle adversarial results and probably allow decrease dosing.
The U.S. scientific trial underway has a focused enrollment of 1,000 sufferers who will probably be adopted for 48 weeks. The randomized and managed open-label examine has two fundamental targets: exhibiting the proportion of sufferers who lose greater than 5% of their physique weight and evaluating complete physique weight reduction within the Allurion balloon group to the burden loss in management group handled with way of life interventions. The trial is evaluating solely the balloon, not the Allurion software program. The examine continues to be enrolling sufferers however Allurion mentioned in securities filings that it expects to hunt FDA approval in 2024.
Allurion revealed in February its plans to go public in SPAC deal. The quantity of capital accessible to the corporate is not only money from the accounts of merger associate Compute Well being. The entire additionally features a personal funding led by RTW Investments, and fairness investments from Medtronic and former Medtronic CEO and present Compute Well being board Chairman Omar Ishrak. Allurion additionally has artificial royalty financing, a mortgage by which repayments are decided by future income, in addition to a secured time period mortgage from an affiliate of Fortress Funding Group. Sooner or later if it so chooses, Allurion has the flexibility to faucet into a further $100 million by way of an fairness facility with Chardan Capital Markets, an funding financial institution.
Gaur mentioned Allurion will use the capital to increase commercialization of its weight reduction system globally within the markets the place it’s accredited and to assist the regulatory work wanted to safe approval within the U.S. Allurion will even proceed investing in analysis and improvement of recent applied sciences, similar to these using generative AI.
Picture by Enterprise Wire
